{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:22:00Z","timestamp":1780446120335,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00520-025-09268-1","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:10:42Z","timestamp":1739981442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of antiemetic corticosteroids on the development of immune-related adverse events caused by chemoimmunotherapy: a multicenter retrospective study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5689-4769","authenticated-orcid":false,"given":"Airi","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimichi","family":"Koutake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tsutsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Yabuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosei","family":"Kawamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Oyamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"9268_CR1","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.22.00825","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh N, Temin S, Baker S Jr et al (2022) Therapy for stage IV non\u2013small-cell lung cancer without driver alterations: ASCO living guideline. J Clin Oncol 40:3323\u20133343. https:\/\/doi.org\/10.1200\/JCO.22.00825","journal-title":"J Clin Oncol"},{"key":"9268_CR2","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J et al (2023) Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:358\u2013376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013","journal-title":"Ann Oncol"},{"issue":"1","key":"9268_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","volume":"35","author":"MA Postow","year":"2015","unstructured":"Postow MA (2015) Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 35(1):76\u201383. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.76","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"9268_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J et al (2020) NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw 18:230\u2013241. https:\/\/doi.org\/10.6004\/jnccn.2020.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"9268_CR5","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"9268_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J (2016) Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"9268_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/pgmj.52.612.631","volume":"52","author":"MW Greaves","year":"1976","unstructured":"Greaves MW (1976) Anti-inflammatory action of corticosteroids. Postgrad Med J 52:631\u2013633. https:\/\/doi.org\/10.1136\/pgmj.52.612.631","journal-title":"Postgrad Med J"},{"key":"9268_CR8","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.celrep.2014.04.041","volume":"7","author":"C Libert","year":"2014","unstructured":"Libert C, Dejager L (2014) How steroids steer T cells. Cell Rep 7:938\u2013939. https:\/\/doi.org\/10.1016\/j.celrep.2014.04.041","journal-title":"Cell Rep"},{"key":"9268_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-005-5390-y","volume":"63","author":"MJ Herold","year":"2006","unstructured":"Herold MJ, McPherson KG, Reichardt HM (2006) Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 63:60\u201372. https:\/\/doi.org\/10.1007\/s00018-005-5390-y","journal-title":"Cell Mol Life Sci"},{"key":"9268_CR10","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"9268_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"9268_CR12","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"9268_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1\u201317. https:\/\/doi.org\/10.1007\/s10147-020-01818-3","journal-title":"Int J Clin Oncol"},{"key":"9268_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","volume":"15","author":"MJ Berger","year":"2017","unstructured":"Berger MJ, Ettinger DS, Aston J et al (2017) NCCN guidelines insights: antiemesis, version 2.2017. J Natl Compr Canc Netw 15:883\u2013893. https:\/\/doi.org\/10.6004\/jnccn.2017.0117","journal-title":"J Natl Compr Canc Netw"},{"key":"9268_CR15","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797. https:\/\/doi.org\/10.1200\/JCO.20.01296","journal-title":"J Clin Oncol"},{"key":"9268_CR16","doi-asserted-by":"publisher","first-page":"e1066062","DOI":"10.1080\/2162402X.2015.1066062","volume":"5","author":"AM Cook","year":"2016","unstructured":"Cook AM, McDonnell AM, Lake RA, Nowak AK (2016) Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology 5:e1066062. https:\/\/doi.org\/10.1080\/2162402X.2015.1066062","journal-title":"Oncoimmunology"},{"key":"9268_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson MND, Sonnemann HM et al (2018) Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer 6:51. https:\/\/doi.org\/10.1186\/s40425-018-0371-5","journal-title":"J Immunother Cancer"},{"key":"9268_CR18","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","volume":"13","author":"SC Scott","year":"2018","unstructured":"Scott SC, Pennell NA (2018) Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 13:1771\u20131775. https:\/\/doi.org\/10.1016\/j.jtho.2018.06.004","journal-title":"J Thorac Oncol"},{"key":"9268_CR19","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer. J Clin Oncol 36:2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"9268_CR20","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","volume":"37","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM (2019) Immune checkpoint inhibitor outcomes for patients with non\u2013small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol 37:1927\u20131934. https:\/\/doi.org\/10.1200\/JCO.19.00189","journal-title":"J Clin Oncol"},{"key":"9268_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","volume":"145","author":"M Skribek","year":"2021","unstructured":"Skribek M, Rounis K, Afshar S et al (2021) Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer 145:245\u2013254. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.012","journal-title":"Eur J Cancer"},{"key":"9268_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2020.12.011","volume":"145","author":"MN Sorial","year":"2021","unstructured":"Sorial MN, Huynh JP, Azzoli CG et al (2021) Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer. Eur J Cancer 145:234\u2013244. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.011","journal-title":"Eur J Cancer"},{"key":"9268_CR23","doi-asserted-by":"publisher","first-page":"111138","DOI":"10.1016\/j.intimp.2023.111138","volume":"125","author":"H Yu","year":"2023","unstructured":"Yu H, Chen J, Zhou Y et al (2023) Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer. Int Immunopharmacol 125:111138. https:\/\/doi.org\/10.1016\/j.intimp.2023.111138","journal-title":"Int Immunopharmacol"},{"key":"9268_CR24","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00262-023-03408-4","volume":"72","author":"A Fujimoto","year":"2023","unstructured":"Fujimoto A, Koutake Y, Hisamatsu D et al (2023) Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study. Cancer Immunol Immunother 72:2169\u20132178. https:\/\/doi.org\/10.1007\/s00262-023-03408-4","journal-title":"Cancer Immunol Immunother"},{"key":"9268_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00280-008-0713-y","volume":"63","author":"S Nakade","year":"2008","unstructured":"Nakade S, Ohno T, Kitagawa J et al (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 63:75\u201383. https:\/\/doi.org\/10.1007\/s00280-008-0713-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"9268_CR26","first-page":"941","volume":"2","author":"I Sekine","year":"1996","unstructured":"Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N (1996) Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 2:941\u2013945","journal-title":"Clin Cancer Res"},{"key":"9268_CR27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med 377:1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"9268_CR28","first-page":"1209","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"BP Schimmer","year":"2011","unstructured":"Schimmer BP, Funder JW (2011) ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York, pp 1209\u20131235","edition":"12"},{"key":"9268_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cpt1975182205","volume":"18","author":"DE Duggan","year":"1975","unstructured":"Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG (1975) Bioavailability of oral dexamethasone. Clin Pharmacol Ther 18:205\u2013209. https:\/\/doi.org\/10.1002\/cpt1975182205","journal-title":"Clin Pharmacol Ther"},{"key":"9268_CR30","unstructured":"Lasagna L (1999) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 9th edn, Vol. 2. Hirokawa syoten, Tokyo,pp 2259"},{"key":"9268_CR31","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3390\/cancers16112159","volume":"16","author":"R Matsukane","year":"2024","unstructured":"Matsukane R, Oyama T, Tatsuta R et al (2024) Real-world prevalence and tolerability of immune-related adverse events in older adults with non-small cell lung cancer: a multi-institutional retrospective study. Cancers (Basel) 16:2159. https:\/\/doi.org\/10.3390\/cancers16112159","journal-title":"Cancers (Basel)"},{"key":"9268_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"9268_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ncprheum0898","volume":"4","author":"C Stahn","year":"2008","unstructured":"Stahn C, Buttgereit F (2008) Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 4:525\u2013533. https:\/\/doi.org\/10.1038\/ncprheum0898","journal-title":"Nat Clin Pract Rheumatol"},{"key":"9268_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","volume":"10","author":"M Zen","year":"2011","unstructured":"Zen M, Canova M, Campana C et al (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305\u2013310. https:\/\/doi.org\/10.1016\/j.autrev.2010.11.009","journal-title":"Autoimmun Rev"},{"key":"9268_CR35","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","volume":"13","author":"K Suresh","year":"2018","unstructured":"Suresh K, Voong KR, Shankar B et al (2018) Pneumonitis in non\u2013small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. J Thorac Oncol 13:1930\u20131939. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2035","journal-title":"J Thorac Oncol"},{"key":"9268_CR36","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1038\/s41388-021-01897-0","volume":"40","author":"Z Xiang","year":"2021","unstructured":"Xiang Z, Zhou Z, Song S et al (2021) Dexamethasone suppresses immune evasion by inducing GR\/STAT3 mediated downregulation of PD-L1 and IDO1 pathways. Oncogene 40:5002\u20135012. https:\/\/doi.org\/10.1038\/s41388-021-01897-0","journal-title":"Oncogene"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-09268-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-09268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:27:19Z","timestamp":1742002039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-09268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["9268"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-09268-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"3 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki for medical and health research involving human participants. Patient data were utilized after providing patients with the option to decline participation via an opt-out form. The requirement for informed consent was waived due to the retrospective nature of the study. The Ethics Review Committee of the Beppu Medical Center approved this study (approval number, 2023\u2013019). Approval was also obtained from the Investigational Review Board of the Central Ethics Review Committee of Kyushu Medical Center (approval number, 23C091) for the seven other hospitals involved in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}